Can I read Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974 on EtoBox?

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974 by Hirotake Shiraiwa; Atsushi Narita; Mika Kamata-Sakurai; Takahiro Ishiguro; Yuji Sano; Naoka Hironiwa; Takashi Tsushima; Hiroaki Segawa; Toshiaki Tsunenari; Yosuke Ikeda; Yoko Kayukawa; Mizuho Noguchi; Tetsuya Wakabayashi; Akihisa Sakamoto; Hiroko Konishi; Taichi Kuramochi; Mika Endo; Kunihiro Hattori; Junichi Nezu; Tomoyuki Igawa is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974 about?

The antibody drug market is rapidly expanding, and various antibody engineering technologies are being developed to create antibodies that can provide better benefit to patients. Although bispecific antibody drugs have been researched for more than 30 years, currently only a limited number of bispecific antibodies have achieved regulatory approval. Of the few successful examples of industrially manufacturing a bispecific antibody, the "common light chain format" is an elegant technology that simplifies the purification of a whole IgG-type bispecific antibody. Using this IgG format, the bispecific function can be introduced while maintaining the natural molecular shape of the antibody. In this article, we will first introduce the outline, prospects, and limitations of the common light chain format. Then, we will describe the identification and optimization process for ERY974, an anti-glypican-3 × anti-CD3ε T cell-redirecting bispecific antibody with a common light chain. This format includes one of Chugai's proprietary technologies, termed ART-Ig technology, which consists of a method to identify a common light chain, isoelectric point (pI) engineering to purify the desired bispecif

Who reads Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974?

Author

Hirotake Shiraiwa; Atsushi Narita; Mika Kamata-Sakurai; Takahiro Ishiguro; Yuji Sano; Naoka Hironiwa; Takashi Tsushima; Hiroaki Segawa; Toshiaki Tsunenari; Yosuke Ikeda; Yoko Kayukawa; Mizuho Noguchi; Tetsuya Wakabayashi; Akihisa Sakamoto; Hiroko Konishi; Taichi Kuramochi; Mika Endo; Kunihiro Hattori; Junichi Nezu; Tomoyuki Igawa

Published

2018

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)